ZVRA Zevra Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ZVRA

Price (delayed)

$11.32

Market cap

$672.22M

P/E Ratio

11.92

Dividend/share

N/A

EPS

$0.95

Enterprise value

$528.4M

?
Relative Growth: Rel. Growth: 85
Relative Strength: Rel. Strength: 68
Relative Valuation: Rel. Valuation: 90
Relative Profitability: Rel. Profitability: 99

Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. Our mission is ...

Highlights
ZVRA's gross profit has soared by 191% YoY and by 23% from the previous quarter
ZVRA's revenue has soared by 119% YoY and by 11% QoQ
ZVRA's debt has dropped by 98% year-on-year but it is up by 30% since the previous quarter
The quick ratio has declined by 34% year-on-year but it has increased by 6% since the previous quarter
Zevra Therapeutics's EPS has shrunk by 54% QoQ
Zevra Therapeutics's net income has shrunk by 53% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://kempharm.com
Peers: OPK ORGO

Key stats

What are the main financial stats of ZVRA

ZVRA stock price

How has the Zevra Therapeutics stock price performed over time
Intraday
-2.25%
1 week
-4.07%
1 month
-4.63%
1 year
39.58%
YTD
26.34%
QTD
-21.06%

Financial performance

How have Zevra Therapeutics's revenue and profit performed over time
Revenue
$136.07M
Gross profit
$129.89M
Operating income
$82.38M
Net income
$58.26M
Gross margin
95.5%
Net margin
42.8%
ZVRA's gross profit has soared by 191% YoY and by 23% from the previous quarter
The operating income has soared by 169% YoY
The operating margin has soared by 131% YoY
ZVRA's revenue has soared by 119% YoY and by 11% QoQ

Price vs fundamentals

How does ZVRA's price correlate with its fundamentals

Growth

What is Zevra Therapeutics's growth rate over time

Valuation

What is Zevra Therapeutics stock price valuation
P/E
11.92
P/B
3.07
P/S
4.92
EV/EBIT
7.05
EV/EBITDA
6.83
EV/Sales
3.88
Zevra Therapeutics's EPS has shrunk by 54% QoQ
ZVRA's price to earnings (P/E) is 6% higher than its last 4 quarters average of 11.5
Zevra Therapeutics's equity has soared by 86% YoY and by 6% from the previous quarter
The price to book (P/B) is 19% lower than the 5-year quarterly average of 3.9 and 10% lower than the last 4 quarters average of 3.5
ZVRA's revenue has soared by 119% YoY and by 11% QoQ
ZVRA's P/S is 53% below its 5-year quarterly average of 10.8 and 7% below its last 4 quarters average of 5.4

Efficiency

How efficient is Zevra Therapeutics business performance
Zevra Therapeutics's return on invested capital has surged by 83% YoY but it has decreased by 37% QoQ
ZVRA's ROE has shrunk by 60% QoQ
The company's return on assets has shrunk by 55% QoQ
Zevra Therapeutics's return on sales has shrunk by 52% QoQ but it has increased by 14% YoY

Dividends

What is ZVRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZVRA.

Financial health

How did Zevra Therapeutics financials performed over time
The total liabilities has contracted by 39% YoY but it has grown by 17% from the previous quarter
The quick ratio has declined by 34% year-on-year but it has increased by 6% since the previous quarter
ZVRA's debt is 99% smaller than its equity
The debt to equity has plunged by 98% YoY
ZVRA's debt has dropped by 98% year-on-year but it is up by 30% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.